BioReference Laboratories
In Brief This Week: PerkinElmer, CDC, Opko, DermTech, OpGen, More
News items for the week of May 1, 2023.
In Brief This Week: Abbott, Thermo Fisher Scientific, Danaher, Oncocyte, Biocartis, More
News items for the week of Feb. 20, 2023.
While reform of lab-developed test regulations and PAMA appeared possible at the beginning of 2022, in the end, the status quo won out.
The firm alleges its competitors infringe its patents describing processes for finding chromosomal abnormalities in fetal cell-free DNA.
Aspira Women's Health, BioReference Ink Distribution Deal for Ovarian Cancer Test
The Ova1Plus test combines two FDA-approved assays that analyze levels of five biomarkers to provide a malignancy risk index.
Aug 31, 2022
Oct 28, 2021
Opko Health Q3 Revenues Fall 10 Percent
Sep 2, 2021
May 6, 2021
Apr 29, 2021
Apr 7, 2021